# Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma

> **NCT00695786** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 156 (actual)

## Conditions studied

- Ann Arbor Stage III Grade 1 Follicular Lymphoma
- Ann Arbor Stage III Grade 2 Follicular Lymphoma
- Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma
- Ann Arbor Stage III Marginal Zone Lymphoma
- Ann Arbor Stage III Small Lymphocytic Lymphoma
- Ann Arbor Stage IV Grade 1 Follicular Lymphoma
- Ann Arbor Stage IV Grade 2 Follicular Lymphoma
- Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Marginal Zone Lymphoma
- Ann Arbor Stage IV Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Lenalidomide
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT00695786
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06-10
- **Primary completion:** 2020-07-11
- **Final completion:** 2020-07-11
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2021-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00695786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00695786, "Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00695786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*